AmerisourceBergen and its now-defunct subsidiary, Medical Initiatives, has plead guilty to illegally distributing misbranded drugs.
According to court records, from 2001 to 2014, the company packaged syringes of cancer drugs at an Alabama facility that was not registered with the U.S. FDA.
Additionally, prosecutors said that Medical Initiatives prepared syringes by pooling drugs sold in glass vials that were meant for a single use, failing to maintain a sterile environment in its facility.
AmerisourceBergen has agreed to pay penalties of $260 million.
Read the Reuters coverage